Copyright © 2019. Inderes Oy. All rights reserved.
Search

Company pages

Olvi Revenio Group Tikkurila Oriola Orion Ramirent Cramo Stora Enso Neste UPM Kemira Valmet Outokumpu YIT Suominen Fortum Aspo Basware Cargotec Elisa Telia company Uponor Solteq Soprano Caverion Metsä Board QPR Software Huhtamäki Raute Tecnotree Siili Solutions Glaston Efore Innofactor Bittium Etteplan Nokia TietoEVRY Stockmann Kone Konecranes Metso Outotec Ponsse Wärtsilä Verkkokauppa.com CapMan Taaleri Fiskars Kesko Nokian Renkaat Rapala VMC Sampo Sanoma Citycon Ovaro Kiinteistösijoitus Apetit NoHo Partners Nixu United Bankers Aspocomp Panostaja Comptel Nexstim Scanfil Detection Technology Talenom Martela SRV eQ Finnair Pihlajalinna Avidly Piippo Investors House Hoivatilat Marimekko Privanet Teleste Uutechnic Sotkamo Silver Vaisala Consti Yhtiöt Vincit Heeros Alma Media Neo Industrial Exel Composites Ahlstrom - Munksjö Qt Fondia Remedy Next Games Afarak Group Endomines SSAB B Componenta Dovre Group Elecster Incap Kesla Lassila & Tikanoja Lehto Group Nurminen Logistics Robit Tulikivi Valoe Wulff-Yhtiöt Yleiselektroniikka Atria HKScan Honkarakenne Raisio Saga Furs Biohit Silmäasema Ilkka-Yhtymä Kamux Keskisuomalainen PunaMusta Media Tokmanni Group Viking Line DNA Aktia Nordea Bank Ålandsbanken Sievi Capital Asiakastieto Group Digia Trainers' House SSH Communications Security Digitalist Group F-Secure Evli Pankki Ahola Transport Loudspring EAB Group Herantis Pharma Savo-Solar Rovio Titanium Terveystalo Gofore Efecte Admicom BBS-Bioactive Bone Substitutes Harvia Altia Enersense NCC Group Ericsson Skanska Atlas Copco Intrum H&M Clas Ohlson Autoliv Kojamo Eezy Tallinna Sadam LHV Tallink Tallinna Vesi Arco Vara Baltika Ekspress Grupp Harju Elekter Merko Ehitus Nordecon Olympic Entertainment Group PRFoods Silvano Fashion Group Skano Group Tallinna Kaubamaja Pro Kapital Grupp Trigon Property Development Fellow Finance Nordic ID Viafin Service Rush Factory Oma Säästöpankki Cibus Nordic Real Estate LeadDesk Aallon Group Adapteo Arctic Minerals Relais Group Fodelia Optomed Faron Pharmaceuticals Bonava Essity

We did not find this company. Try another name.

Recent updates

User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Orion
6396 investors follow this company
BUY 43.91 LOWEST 43.40 VOLUME 398 621
SELL 43.94 HIGHEST 44.09 VALUE 17,482 Milj. EUR

Would you like to see our recommendations and target prices?

Luo FREE-tiliOsta PREMIUM-tili

You already have an Inderes account? Log in from here.

Analyytikko

Petri Kajaani
+358 50 527 8680

Upcoming events

5
Feb
Tilinpäätöstiedotteet

Forum

Latest insider trading

Article
Company post
Type: stock_exchange_release
Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation
22.1.
2020

ORION CORPORATION  STOCK EXCHANGE RELEASE 22 JANUARY 2020 at 12.45 EET
        

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation

Type: stock_exchange_release
Orion publishes Financial Statement Release for 2019 on 5 February 2020
22.1.
2020

ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET             
         
Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Type: stock_exchange_release
228,223 Orion Corporation A shares converted into B shares
21.1.
2020

ORION CORPORATION STOCK EXCHANGE RELEASE 21 JANUARY 2020 at 9.00 EET             
         
228,223 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 228,223 A shares have been converted into 228,223 B shares. The conversion has been entered into the Trade Register on 21 January 2020.

Type: stock_exchange_release
Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia
30.12.
2019

ORION CORPORATION PRESS RELEASE 30 DECEMBER 2019 at 9.00 EET             
         

Orion Corporation (“Orion”) and Lotus Pharmaceutical Co., Ltd. (“Lotus”) have made a marketing and distribution agreement for Orion’s Parkinson’s disease drugs Stalevo® and Comtan® in parts of Asia.

Type: stock_exchange_release
33,944 Orion Corporation A shares converted into B shares
18.12.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 18 DECEMBER 2019 at 10.15 EET             
         
33,944 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 33,944 A shares have been converted into 33,944 B shares. The conversion has been entered into the Trade Register on 18 December 2019.

Type: stock_exchange_release
Orion Corporation: Managers’ transactions – Sydäntutkimussäätiö sr.
13.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 13 December 2019 at 15.15 EET

Orion Corporation: Managers’ transactions – Sydäntutkimussäätiö sr.

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
Orion Corporation: Managers’ transactions – Mikael Silvennoinen
9.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 9 December 2019 at 10.45 EET

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
Orion Corporation: Managers’ transactions – Agendum Oy
9.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 09 December 2019 at 10.30 EET

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
9.12.
2019

Orion Corporation                        Press release                               9 December at 10.15 EET

Type: stock_exchange_release
Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND
2.12.
2019

Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND

Orion Corporation                        Press release                               2 December 2019 at 1.00 p.m. EET

Orion

Orion lyhyesti

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.